navan
/
Daily-Dose
mirror of https://github.com/navanchauhan/Daily-Dose.git
1
0
Fork 0
Code Issues Projects Releases Wiki Activity

Added daily report

This commit is contained in:
Navan Chauhan 2021-01-22 13:21:36 +00:00
parent c8059e68b6
commit 625a8e8712
3 changed files with 667 additions and 2 deletions
Show Stats Download Patch File Download Diff File Expand all files Collapse all files

211
archive-covid-19/22 January, 2021.html Normal file
View File

@ -0,0 +1,211 @@
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><head>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<meta content="text/css" http-equiv="Content-Style-Type"/>
<meta content="pandoc" name="generator"/>
<title></title>
<style type="text/css">code{white-space: pre;}</style>
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-preprints">From Preprints</a></li>
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
<li><a href="#from-pubmed">From PubMed</a></li>
<li><a href="#from-patent-search">From Patent Search</a></li>
</ul>
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
<ul>
<li><strong>Pressure Injury Prevention in COVID-19 Patients with Acute Respiratory Distress Syndrome</strong> -
<div>
There is a global health professional knowledge deficit on pressure injury (PI) prevention and early detection and standard preventive interventions recommended by the clinical practice guidelines may not be fully implemented, which is applicable to the COVID-19 situation. Health professionals may lack awareness of pressure points typical for patients in prone position and may have misconceptions related to specific equipment required for prone positioning. In this perspective article, we summarize the best recommendations for prevention of PI in SARS-CoV-2 infected acute respiratory distress syndrome (ARDS) patients in the prone positioning.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/xk5rw/" target="_blank">Pressure Injury Prevention in COVID-19 Patients with Acute Respiratory Distress Syndrome</a>
</div></li>
<li><strong>Non-steroidal Anti-inflammatory Drugs Potential Effects on the Interleukin-6 Amplifier, NF-κB Pathway and Nitric Oxide to Prevent the Development of Cytokine storm: Genetic Results Interpretations Versus Pharmacovigilant Real-life Practice.</strong> -
<div>
Pairo-Castineira et al. have recently demonstrated that altered expression of certain genes related to the immune and inflammatory systems reduced the odds of severe COVID-19 and protected against it; we agree with their results from a clinical perspective. However, they have suggested some drugs, including barictinib, to be of priority to be tested basing on their results. We present a concise analysis of these results according to our real-life and academic experience that disagree with some of their recommendations from a clinical and pharmacovigilant point of view. Further, we confirm that the important results released Pairo-Castineira et al. confirm the validity to our recommended real-life adopted protocol, which is basing on our academically published studies, using non-steroidal anti-inflammatory drugs, nitazoxanide and azithromycin to safely manage COVID-19 patients.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/b5sgp/" target="_blank">Non-steroidal Anti-inflammatory Drugs Potential Effects on the Interleukin-6 Amplifier, NF-κB Pathway and Nitric Oxide to Prevent the Development of Cytokine storm: Genetic Results Interpretations Versus Pharmacovigilant Real-life Practice.</a>
</div></li>
<li><strong>We distance most when our close circle does, not when we think we should</strong> -
<div>
Why do we adopt new rules, such as social distancing? Although human sciences research stresses the key role of social influence in behaviour change, most COVID-19 campaigns emphasise the disease’s medical threat. In a global dataset (n= 6675), we investigated how social influences predict people’s adherence to distancing rules during the pandemic. Bayesian regression analyses controlling for stringency of local measures showed that people distanced most when they thought their close social circle did. Such social influence mattered more than people thinking distancing was the right thing to do. People’s adherence also aligned with their fellow citizens’, but only if they felt deeply bonded with their country. Self-vulnerability to the disease predicted distancing more for people with larger social circles. Collective efficacy and collectivism also significantly predicted distancing. To achieve behavioural change during crises, policymakers must emphasise shared values and harness the social influence of close friends and family.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://psyarxiv.com/u74wc/" target="_blank">We distance most when our close circle does, not when we think we should</a>
</div></li>
<li><strong>The psychosocial impact of the COVID-19 pandemic on 4,378 UK healthcare workers and ancillary staff: initial baseline data from a cohort study collected during the first wave of the pandemic.</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Objectives This study reports preliminary findings on the prevalence of, and factors associated with, mental health and wellbeing outcomes of healthcare workers during the early months (April-June) of the COVID-19 pandemic in the UK. Methods Preliminary cross-sectional data were analysed from a cohort study (n=4,378). Clinical and non-clinical staff of three London-based NHS Trusts (UK), including acute and mental health Trusts, took part in an online baseline survey. The primary outcome measure used is the presence of probable common mental disorders (CMDs), measured by the General Health Questionnaire (GHQ-12). Secondary outcomes are probable anxiety (GAD-7), depression (PHQ-9), Post-Traumatic Stress Disorder (PTSD) (PCL-6), suicidal ideation (CIS-R), and alcohol use (AUDIT). Moral injury is measured using the Moray Injury Event Scale (MIES). Results Analyses showed substantial levels of CMDs (58.9%, 95%CI 58.1 to 60.8), and of PTSD (30.2%, 95%CI 28.1 to 32.5) with lower levels of depression (27.3%, 95%CI 25.3 to 29.4), anxiety (23.2%, 95%CI 21.3 to 25.3), and alcohol misuse (10.5%, 95%CI, 9.2 to 11.9). Women, younger staff, and nurses tended to have poorer outcomes than other staff, except for alcohol misuse. Higher reported exposure to moral injury (distress resulting from violation of one9s moral code) was strongly associated with increased levels of CMDs, anxiety, depression, PTSD symptoms, and alcohol misuse. Conclusions Our findings suggest that mental health support for healthcare workers should consider those demographics and occupations at highest risk. Rigorous longitudinal data are needed in order to respond to the potential long-term mental health impacts of the pandemic.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.01.21.20240887v1" target="_blank">The psychosocial impact of the COVID-19 pandemic on 4,378 UK healthcare workers and ancillary staff: initial baseline data from a cohort study collected during the first wave of the pandemic.</a>
</div></li>
<li><strong>Symptoms of anxiety and depression in relation to work patterns during the first wave of the COVID-19 epidemic in Philadelphia PA: a cross-sectional survey</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Objective: We investigated whether patterns of work during COVID-19 pandemic altered by effort to contain the outbreak affected anxiety and depression. Methods: We conducted a cross-sectional online survey of 911 residents of Philadelphia, inquiring about their working lives during early months of the epidemic, symptoms of anxiety and depression, plus demographics, perceived sources of support, and general health. Results: Occupational contact with suspected COVID-19 cases was associated with anxiety. Concerns about return to work, childcare, lack of sick leave, and loss/reduction in work correlated with anxiety and depression, even when there was no evidence of occupational contact with infected persons; patterns differed by gender. Conclusions: Heightened anxiety and depression during COVID-19 pandemic can be due to widespread disruption of working lives, especially in non-essential low-income industries, on par with experience in healthcare.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.01.21.21250117v1" target="_blank">Symptoms of anxiety and depression in relation to work patterns during the first wave of the COVID-19 epidemic in Philadelphia PA: a cross-sectional survey</a>
</div></li>
<li><strong>Redeployment and training of healthcare professionals to Intensive Care during COVID-19: a systemic review</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: A rapid influx of patients to intensive care and infection control measures during the COVID-19 pandemic required the rapid development of innovative redeployment and training strategies. Methods: We conducted a systematic search of 9 databases including key terms related to intensive care AND training AND redeployment AND healthcare workers. Analysis consisted of a narrative synthesis of quantitative study outputs, and a framework-based thematic analysis of qualitative study outputs and grey literature. These results were then combined applying an interpretative synthesis. Results: Twenty papers were analysed. These took place primarily in the UK (N=8, 40%) and USA (N=5, 25%). Themes included in the results are Redeployment: Implementation strategies and learnings; Redeployed staff experience and strategies to address their needs; Redeployed staff learning needs; Training formats offered and training evaluations; and Future redeployment and training concerns. Some of the redeployment implementation and training strategies documented in this review are: Skills-based redeployment, buddy support systems, and agreeing on locally-specific principles, rather than strict procedures. Conclusion: The COVID-19 pandemic presented unique challenges to deliver training promptly while following infection control recommendations and develop flexible redeployment strategies. This study synthesises original approaches to tackle these challenges which are relevant to inform the development of targeted and adaptative training and redeployment plans.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.01.21.21250230v1" target="_blank">Redeployment and training of healthcare professionals to Intensive Care during COVID-19: a systemic review</a>
</div></li>
<li><strong>Longitudinal trends and risk factors for depressed mood among Canadian adults during the first wave of COVID-19</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: The COVID-19 pandemic has raised serious concerns about the mental health impact of people directed and indirectly affected by the virus. Because this is a rapidly evolving situation, our goal was to explore potential risk factors and trends in feelings of anxiety and depression among the general population in Canada over the first five months of the pandemic. Methods: We completed on-line surveys of 3,127 unique individuals representative of the Canadian general population at 4 discreet periods every 6 weeks from April 15th to July 28th 2020. We assessed feelings of anxiety, depression and loss of interest with the interRAI self-reported mood scale using a multivariable generalized estimating equation model to examine factors associated with having a 5+ score on the scale (indicating potentially depressed mood). We also investigated potential longitudinal trends to examine temporal changes in mood scores. Results: More than 30% of participants felt highly anxious, depressed, and disinterested in everyday activities in the first survey (April), but this number decreased to about 20% over 4 months. Feeling lonely, younger age, feeling overwhelmed by one9s health needs, having financial concerns, and living outside of Québec were significantly associated with depressed mood. Interpretation: The prevalence of depressed mood during the pandemic was between 2 and 3 times the pre-pandemic rate (especially among young people), but it can change rapidly in response to social changes. Thus, monitoring of psychological distress among vulnerable groups that may benefit from additional supports should be a priority.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.01.21.20245795v1" target="_blank">Longitudinal trends and risk factors for depressed mood among Canadian adults during the first wave of COVID-19</a>
</div></li>
<li><strong>A cross-sectional analysis of demographic and behavioral risk factors of SARS-CoV-2 antibody positivity among a sample of U.S. college students</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: Colleges and universities across the United States are developing and implementing data-driven prevention and containment measures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Identifying risk factors for SARS-CoV-2 seropositivity could help to direct these efforts. Objective: To estimate the associations between demographic factors and social behaviors and SARS-CoV-2 seropositivity and self-reported positive SARS-CoV-2 diagnostic test. Methods: In September 2020, we randomly sampled Indiana University Bloomington (IUB) undergraduate students. Participants completed a cross-sectional, online survey about demographics, SARS-CoV-2 testing history, relationship status, and risk behaviors. Additionally, during a subsequent appointment, participants were tested for SARS-CoV-2 antibodies using a fingerstick procedure and SARS-CoV-2 IgM/IgG rapid assay kit. We used unadjusted modified Poisson regression models to evaluate the associations between predictors of both SARS-CoV-2 seropositivity and self-reported positive SARS-CoV-2 infection history. Results: Overall, 1,076 students were included in the serological testing analysis, and 1,239 students were included in the SARS-CoV-2 infection history analysis. Current seroprevalence of SARS-CoV-2 was 4.6% (95% CI: 3.3%, 5.8%). Prevalence of self-reported SARS-CoV-2 infection history was 10.3% (95% CI: 8.6%, 12.0%). Greek membership, having multiple romantic partners, knowing someone in one9s immediate environment with SARS-CoV-2 infection, drinking alcohol more than 1 day per week, and hanging out with more than 4 people when drinking alcohol increased both the likelihood of seropositivity and SARS-CoV-2 infection history. Conclusion: Our findings have implications for American colleges and universities and could be used to inform SARS-C0V-2 prevention and control strategies on such campuses.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.01.20.21249905v1" target="_blank">A cross-sectional analysis of demographic and behavioral risk factors of SARS-CoV-2 antibody positivity among a sample of U.S. college students</a>
</div></li>
<li><strong>Exploring support needs of people living with diabetes during the coronavirus COVID-19 pandemic: insights from a UK survey.</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background The coronavirus COVID-19 pandemic has radically compromised healthcare for people living with chronic conditions such as diabetes. Government-imposed restrictions to contain the spread of the virus has forced people to suddenly adjust their lifestyle. This study aimed to capture the impact of the pandemic on people living with diabetes and the views of these individuals on ways in which the information, advice and support they are receiving could be improved. Research design and methods An online anonymous survey was distributed across the UK during the first lockdown and initial easing. The survey comprised questions about confidence in diabetes self-management, resources used to obtain information, advice and support, and opinions on how these could be improved. Open-ended captured subjective experiences. Results The survey was completed by 773 adults living with diabetes (69.2% type 1, 28.5% type 2). There was notable variability in the impact of the pandemic on confidence in self-management, with confidence having deteriorated most commonly in the ability to take care of own mental wellbeing (37.0% respondents) and improved most commonly in maintaining a healthy weight (21.1% respondents). 41.2% of respondents living alone reported not receiving any outside support. The quality of information, advice and support received from the healthcare team was rated poorly by 37.2%. Respondents sought greater communication and tailored advice from their care team, clear and consistent information from the government and news channels, and improved understanding of diabetes and its challenges from their personal networks and employers. Conclusion Adjusting to the COVID-19 pandemic has strained the mental health and wellbeing of people living with diabetes. Diabetes care teams must receive assistance to support these individuals without risking further inequalities in access to healthcare. Equipping personal networks and employers with knowledge on diabetes and skills to support self-management may reduce the burden on the NHS.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.01.20.21249888v1" target="_blank">Exploring support needs of people living with diabetes during the coronavirus COVID-19 pandemic: insights from a UK survey.</a>
</div></li>
<li><strong>REACT-1 round 8 interim report: SARS-CoV-2 prevalence during the initial stages of the third national lockdown in England</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background High prevalence of SARS-CoV-2 virus in many northern hemisphere populations is causing extreme pressure on healthcare services and leading to high numbers of fatalities. Even though safe and effective vaccines are being deployed in many populations, the majority of those most at-risk of severe COVID-19 will not be protected until late spring, even in countries already at a more advanced stage of vaccine deployment. Methods The REal-time Assessment of Community Transmission study-1 (REACT-1) obtains throat and nose swabs from between 120,000 and 180,000 people in the community in England at approximately monthly intervals. Round 8a of REACT-1 mainly covers a period from 6th January 2021 to 15th January 2021. Swabs are tested for SARS-CoV-2 virus and patterns of swab-positivity are described over time, space and with respect to individual characteristics. We compare swab-positivity prevalence from REACT-1 with mobility data based on the GPS locations of individuals using the Facebook mobile phone app. We also compare results from round 8a with those from round 7 in which swabs were collected from 13th November to 24th November (round 7a) and 25th November to 3rd December 2020 (round 7b). Results In round 8a, we found 1,962 positives from 142,909 swabs giving a weighted prevalence of 1.58% (95% CI, 1.49%, 1.68%). Using a constant growth model, we found no strong evidence for either growth or decay averaged across the period; rather, based on data from a limited number of days, prevalence may have started to rise at the end of round 8a. Facebook mobility data showed a marked decrease in activity at the end of December 2020, followed by a rise at the start of the working year in January 2021. Between round 7b and round 8a, prevalence increased in all adult age groups, more than doubling to 0.94% (0.83%, 1.07%) in those aged 65 and over. Large household size, living in a deprived neighbourhood, and Black and Asian ethnicity were all associated with increased prevalence. Both healthcare and care home workers, and other key workers, had increased odds of swab-positivity compared to other workers. Conclusion During the initial 10 days of the third COVID-19 lockdown in England in January 2021, prevalence of SARS-CoV-2 was very high with no evidence of decline. Until prevalence in the community is reduced substantially, health services will remain under extreme pressure and the cumulative number of lives lost during this pandemic will continue to increase rapidly.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.01.20.21250158v1" target="_blank">REACT-1 round 8 interim report: SARS-CoV-2 prevalence during the initial stages of the third national lockdown in England</a>
</div></li>
<li><strong>Early detection of SARS-CoV-2 infection cases or outbreaks at nursing homes by targeted wastewater tracking</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Objectives: Near-source tracking of SARS-CoV-2 RNA in the sewage drains serving particular buildings may allow rapid identification of SARS-CoV-2 infection cases or local outbreaks. In this pilot study, we investigated whether this was the case for nursing homes (NH). Methods: The study involved five NH (from A to E) affiliated to the Clinico-Malvarrosa Health Department, Valencia (Spain). These were nursing or mixed nursing/care homes of different sizes, altogether providing care for 472 residents attended by a staff of 309. Near-source sewage samples were screened for presence of SARS-CoV-2 RNA by RT-qPCR at least 5 days per week during the study period. SARS-CoV-2 RNA testing in nasopharyngeal swabs from residents and staff was performed with the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, Massachusetts, USA). Results: SARS-CoV-2 RNA was detected in wastewater samples from four of the five NH. SARS-CoV-2 infection cases were documented in three of these four NH. Of the two NH without SARS-CoV-2 infection cases, no SARS-CoV-2 RNA was detected in sewer samples from one facility, while it was repeatedly detected in samples from the other. Presence of SARS-CoV-2 RNA in sewage preceded identification of isolated cases among residents or staff or outbreak declaration in two NH, with lag times ranging from 5 to 19 days. Conclusion: Our study demonstrated that intermittent or persistent detection of SARS-CoV-2 RNA in NH sewers can provide an early warning of subsequent individual cases or outbreaks in these facilities.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.01.21.21249640v1" target="_blank">Early detection of SARS-CoV-2 infection cases or outbreaks at nursing homes by targeted wastewater tracking</a>
</div></li>
<li><strong>Clinical prediction rule for SARS-CoV-2 infection from 116 U.S. emergency departments</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Objectives: Accurate and reliable criteria to rapidly estimate the probability of infection with the novel coronavirus-2 that causes the severe acute respiratory syndrome (SARS-CoV-2) and associated disease (COVID-19) remain an urgent unmet need, especially in emergency care. The objective was to derive and validate a clinical prediction rule for SARS-CoV-2 infection that uses simple criteria widely available at the point of care. Methods: Data came from the Registry data from the national REgistry of suspected COVID-19 in EmeRgency care (RECOVER network) comprising 116 hospitals from 25 states in the US. Clinical predictors and 30-day outcomes were abstracted from medical records of 19,850 emergency department (ED) patients tested for SARS-CoV-2. The criterion standard for diagnosis of SARS-CoV-2 required a positive molecular test from a swabbed sample or positive antibody testing within 30 days. The prediction rule was derived from a 50% random sample (n=9,925) using unadjusted analysis of 107 candidate variables as a screening step, followed by stepwise forward logistic regression on 72 variables. Results: Multivariable regression yielded a 13-variable score, which was simplified to 13-point rule: +1 point each for age&gt;50 years, measured temperature&gt;37.5 degrees C, oxygen saturation&lt;95%, Black race, Hispanic or Latino ethnicity, household contact with known or suspected COVID-19, patient reported history of dry cough, anosmia/dysgeusia, myalgias or fever; and -1 point each for White race, no direct contact with infected person, or smoking. In the validation sample (n=9,975), the score produced an area under the receiver operating character curve of 0.80 (95% CI: 0.79-0.81), and this level of accuracy was retained across patients enrolled from the early spring to summer of 2020. In the simplified rule, a score of zero produced a sensitivity of 95.6% (94.8-96.3%), specificity of 20.0% (19.0-21.0%), likelihood ratio negative of 0.22 (0.19-0.26). Increasing points on the simplified rule predicted higher probability of infection (e.g., &gt;75% probability with +5 or more points). Conclusion: Criteria that are available at the point of care can accurately predict the probability of SARS-CoV-2 infection. These criteria could assist with decision about isolation and testing at high throughput checkpoints.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.01.20.21249656v1" target="_blank">Clinical prediction rule for SARS-CoV-2 infection from 116 U.S. emergency departments</a>
</div></li>
<li><strong>Clinical effectiveness of convalescent plasma in hospitalized patients with COVID-19: a systematic review and meta-analysis</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Given the variability of previously reported results, this systematic review aims to determine the clinical effectiveness of convalescent plasma employed in the treatment of hospitalized patients with diagnosis of COVID-19. We conducted a systematic review of controlled clinical trials assessing treatment with convalescent plasma for hospitalized patients with a diagnosis of SARS-CoV-2 infection. The outcomes were mortality, clinical improvement, and ventilation requirement. A total of 50 studies were retrieved from the databases. Four articles were finally included in the data extraction, qualitative and quantitative synthesis of results. The meta-analysis suggests that there is no benefit of convalescent plasma compared to standard care or placebo in the reduction of the overall mortality and in the ventilation requirement; but there could be a benefit for the clinical improvement in patients treated with plasma. We can conclude that the convalescent plasma transfusion cannot reduce the mortality or ventilation requirement in hospitalized patients diagnosed with SARS-CoV-2 infection. More controlled clinical trials conducted with methodologies that ensure a low risk of bias are still needed.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.01.16.21249956v1" target="_blank">Clinical effectiveness of convalescent plasma in hospitalized patients with COVID-19: a systematic review and meta-analysis</a>
</div></li>
<li><strong>Initial impacts of COVID-19 on youth offending: An exploration of differences across communities</strong> -
<div>
A number of international studies have found that the initial stages of the COVID-19 pandemic were associated with reductions in crime, primarily due to changes in the routine activities of the population. However, to date there has been no targeted exploration of how COVID-19 may have influenced youth offending, which may be more heavily impacted by the changes heralded by COVID-19 containment measures. This study examines changes in youth offending in an Australia jurisdiction, Queensland, following the implementation of COVID-19 containment measures from the period April to June, 2020. Additionally, differences in impacts across community types were explored. Findings from panel regression indicated significant declines in youth property offending, offences against the person and public order offences in this period, but no significant changes in illicit drug offences. There were also significant differences across communities according to socio-economic status, per cent Indigenous population, and the extent of commercial or industrial land use. Findings are explored with reference to environmental crime theories and the potential impacts of social, economic and policing changes that occurred in this period.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/preprints/socarxiv/59bzv/" target="_blank">Initial impacts of COVID-19 on youth offending: An exploration of differences across communities</a>
</div></li>
<li><strong>Reflection of COVID Frontline Worker based on family’s experience with COVID infection</strong> -
<div>
The covid-19 pandemic created fear for everyone because no vaccine was available; no treatment protocol for COVID-19 patients was foolproof. In this report, the experience of the family of Covid frontline workers is described. Dr. Madhusudana is a scientist in a Medical College in Andhra Pradesh and his wife Mrs shobharani works as Nursing Staff in the Medical College. The Hospital is declared a COVID Hospital. Thus, both are front line workers during the current COVID-19 Pandemic. This created panic in the family in the same way as in almost every individual in any other family. In this article, the treatment and prophylaxis experience of a family of COVID-19 frontline workers is reported. It is hoped that such reports help other Covid frontline workers to take preventive measures to control the COVID-19 and enhances their confidence in coping with the infection and reduces their stress. The current diagnosis for COVID-19 in India is by RT-PCR test and, Trunat Rapid test kit. Treatment procedures are different based on the severity of the patient. Mrs. Shobharani tested Covid-19 positive on 11th August 2020. Immediately she rushed to the designated covid-Out Patient Department of a COVID Hospital. After evaluation, she opted and was permitted for home quarantine with treatment as per protocol current at that time.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/nsm2u/" target="_blank">Reflection of COVID Frontline Worker based on family’s experience with COVID infection</a>
</div></li>
</ul>
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Dexamethasone for COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Drug: Dexamethasone<br/><b>Sponsor</b>:   University of Oklahoma<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Placebo;   Drug: Fluvoxamine<br/><b>Sponsor</b>:   SigmaDrugs Research Ltd.<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Ivermectin 0.6mg/kg/day;   Drug: Ivermectin 1.0mg/kg/day;   Drug: Placebo;   Drug: Hydroxychloroquine<br/><b>Sponsor</b>:   Corpometria Institute<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>APT™ T3X on the COVID-19 Contamination Rate</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: Tetracycline hydrochloride 3%;   Drug: Placebo<br/><b>Sponsors</b>:   University of Nove de Julho;   Santa Casa de Misericórdia de Porto Alegre<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: ORTD-1 low dose;   Drug: ORTD-1 mid dose;   Drug: ORTD-1 high dose;   Other: Vehicle control<br/><b>Sponsor</b>:   Oryn Therapeutics, LLC<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Rapid Diagnosis of COVID-19 by Chemical Analysis of Exhaled Air</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Diagnostic Test: Performance evaluation (sensitivity and specificity) for COVID-19 diagnosis of the Vocus PTR-TOF process<br/><b>Sponsor</b>:   Hospices Civils de Lyon<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Immunologic Antiviral Therapy With Omalizumab</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Biological: Omalizumab;   Other: Placebo<br/><b>Sponsor</b>:   McGill University Health Centre/Research Institute of the McGill University Health Centre<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>IMUNOR® Preparation in the Prevention of COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Drug: IMUNOR<br/><b>Sponsor</b>:   University Hospital Ostrava<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Vitamin C 500 MG Oral Tablet;   Drug: Tenofovir disoproxyl fumarate 300 MG Oral Tablet;   Drug: Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet<br/><b>Sponsors</b>:   Universidade Federal do Ceara;   Conselho Nacional de Desenvolvimento Científico e Tecnológico;   São José Hospital for Infectious Diseases - HSJ;   Central Laboratory of Public Health of Ceará - Lacen-CE<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: Doxycycline Tablets;   Drug: Rivaroxaban 15Mg Tab;   Combination Product: Hydroxychloroquine and Azithromycin<br/><b>Sponsor</b>:   Yaounde Central Hospital<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Phase Ⅱb Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: Recombinant COVID-19 vaccine (Sf9 cells);   Biological: Placebo<br/><b>Sponsors</b>:   Jiangsu Province Centers for Disease Control and Prevention;   West China Hospital<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Artecom® (pyronaridine-artesunate);   Drug: Placebo<br/><b>Sponsor</b>:   Shin Poong Pharmaceutical Co. Ltd.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Participants ≥ 60 Years of Age and Hospitalized With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: BGE-175;   Other: Placebo<br/><b>Sponsor</b>:   BioAge Labs, Inc.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Betadine© bucal 100 mg/ml;   Drug: Oximen® 3%;   Drug: Clorhexidine Dental PHB©;   Drug: Vitis Xtra Forte©;   Drug: Distilled Water<br/><b>Sponsors</b>:   Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana;   Hospital Universitario Fundación Jiménez Díaz;   Hospital Universitario General de Villalba;   Hospital Universitario Infanta Elena;   Hospital Universitario Virgen de la Arrixaca;   Hospital Clínico Universitario de Valencia;   Dentaid SL<br/><b>Completed</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia</strong> - <b>Condition</b>:   COVID-19 Pneumonia<br/><b>Intervention</b>:   Drug: Cefditoren pivoxil 400mg<br/><b>Sponsor</b>:   Meiji Pharma Spain S.A.<br/><b>Recruiting</b></p></li>
</ul>
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Cholesterol 25-hydroxylase suppresses porcine deltacoronavirus infection by inhibiting viral entry</strong> - Cholesterol 25-hydroxylase (CH25 H) is a key enzyme regulating cholesterol metabolism and also acts as a broad antiviral host restriction factor. Porcine deltacoronavirus (PDCoV) is an emerging swine enteropathogenic coronavirus that can cause vomiting, diarrhea, dehydration and even death in newborn piglets. In this study, we found that PDCoV infection significantly upregulated the expression of CH25H in IPI-FX cells, a cell line of porcine ileum epithelium. Overexpression of CH25H inhibited...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: implication of herb-drug interactions in COVID-19 pharmacotherapy</strong> - Corona Virus Disease 2019 (COVID-19) has spread all over the world and brings significantly negative effects on human health. To fight against COVID-19 in a more efficient way, drug-drug or drug-herb combinations are frequently used in clinical settings. The concomitant use of multiple medications may trigger clinically relevant drug/herb-drug interactions. This study aims to assay the inhibitory potentials of Qingfei Paidu decoction (QPD, a Chinese medicine compound formula recommended for...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Targeting SARS-CoV-2 Viral Proteases as a Therapeutic Strategy to Treat COVID-19</strong> - The 21^(st) century has witnessed three outbreaks of coronavirus (CoVs) infections caused by severe acute respiratory syndrome (SARS)-CoV, Middle East respiratory syndrome (MERS)-CoV and SARS-CoV-2. Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, spreads rapidly and since the discovery of the first COVID-19 infection in December 2019, has caused 1.2 million deaths worldwide and 226,777 deaths in the United States alone. The high amino acid similarity between SARS-CoV-1 and SARS-CoV-2...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice</strong> - CONCLUSIONS: Further randomized trials are needed to answer definitely the question of whether RAS inhibitors are harmful or beneficial to patients with COVID-19.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase</strong> - Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a global pandemic. RNA-dependent RNA polymerase (RdRp) is the key component of the replication or transcription machinery of coronavirus. Therefore SARS-CoV-2-RdRp has been chosen as an important target for the development of antiviral drug(s). During the early pandemic of the COVID-19, chloroquine and hydroxychloroquine were suggested by the researchers for the prevention or...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19</strong> - No abstract</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents</strong> - Emerging outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is a major threat to public health. The morbidity is increasing due to lack of SARS-CoV-2 specific drugs. Herein, we have identified potential drugs that target the 3-chymotrypsin like protease (3CLpro), the main protease that is pivotal for the replication of SARS-CoV-2. Computational molecular modeling was used to screen 3987 FDA approved drugs, and 47 drugs were selected to study their inhibitory...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery</strong> - SARS-CoV-2 is the pathogen responsible for the COVID-19 pandemic. The SARS-CoV-2 papain-like cysteine protease (PLpro) has been implicated in playing important roles in virus maturation, dysregulation of host inflammation, and antiviral immune responses. The multiple functions of PLpro render it a promising drug target. Therefore, we screened a library of approved drugs and also examined available inhibitors against PLpro. Inhibitor GRL0617 showed a promising in vitro IC(50) of 2.1 μM and an...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial</strong> - BACKGROUND: SARS-CoV-2, the virus that causes COVID-19, enters the cells through a mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein highly expressed in the lungs. The putative viral-induced inhibition of ACE2 could result in the defective degradation of bradykinin, a potent inflammatory substance. We hypothesize that increased bradykinin in the lungs is an important mechanism driving the development of pneumonia and respiratory failure in COVID-19.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2</strong> - SARS-CoV-2, a novel coronavirus causing overwhelming death and infection worldwide, has emerged as a pandemic. Compared to its predecessor SARS-CoV, SARS-CoV-2 is more infective for being highly contagious and exhibiting tighter binding with host angiotensin-converting enzyme 2 (hACE-2). The entry of the virus into host cells is mediated by the interaction of its spike protein with hACE-2. Thus, a peptide that has a resemblance to hACE-2 but can overpower the spike protein-hACE-2 interaction...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial</strong> - Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called Coronavirus Disease 2019 (COVID-19). Control of SARS-CoV-2 spread will depend on vaccine-induced or naturally acquired protective herd immunity. Until then, antiviral strategies are needed to manage COVID-19, but approved antiviral treatments, such as remdesivir, can only be delivered intravenously. Enisamium (laboratory code FAV00A, trade name Amizon®) is an orally active inhibitor of influenza A and B viruses in cell...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension</strong> - The COVID-19 infection has rapidly spread around the world and a second wave is sweeping in many countries. Different clinical and epidemiological aspects characterize the disease and their understanding is necessary to better face the management of the pandemic in progress. The Italian society of arterial hypertension with the SARS-RAS study has contributed significantly to the knowledge of the interaction between inhibition of the renin-angiotensin system and COVID-19 infection. Furthermore,...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2</strong> - SARS-CoV-2 entry into host cells is orchestrated by the spike (S) glycoprotein that contains an immunodominant receptor-binding domain (RBD) targeted by the largest fraction of neutralizing antibodies (Abs) in COVID-19 patient plasma. Little is known about neutralizing Abs binding to epitopes outside the RBD and their contribution to protection. Here, we describe 41 human monoclonal Abs (mAbs) derived from memory B cells, which recognize the SARS-CoV-2 S N-terminal domain (NTD) and show that a...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Accurate bulk quantitation of droplet digital PCR</strong> - Droplet digital PCR provides superior accuracy in nucleic acid quantitation. The requirement of microfluidics to generate and analyze the emulsions, however, is a barrier to its adoption, particularly in low resource or clinical settings. Here, we report a novel method to prepare ddPCR droplets by vortexing and readout the results by bulk analysis of recovered amplicons. We demonstrate the approach by accurately quantitating SARS-CoV-2 sequences using entirely bulk processing and no...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Tropism of SARS-CoV-2 for Developing Human Cortical Astrocytes</strong> - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) readily infects a variety of cell types impacting the function of vital organ systems, with particularly severe impact on respiratory function. It proves fatal for one percent of those infected. Neurological symptoms, which range in severity, accompany a significant proportion of COVID-19 cases, indicating a potential vulnerability of neural cell types. To assess whether human cortical cells can be directly infected by SARS-CoV-2,...</p></li>
</ul>
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 CLASSIFICATION RECOGNITION METHOD BASED ON CT IMAGES OF LUNGS</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU314054415">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A traditional Chinese medicine composition for COVID-19 and/or influenza and preparation method thereof</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU313300659">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Covid 19 - Chewing Gum</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU313269181">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>STOCHASTIC MODEL METHOD TO DETERMINE THE PROBABILITY OF TRANSMISSION OF NOVEL COVID-19</strong> - The present invention is directed to a stochastic model method to assess the risk of spreading the disease and determine the probability of transmission of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN313339294">link</a></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Fahrzeuglüftungssystem und Verfahren zum Betreiben eines solchen Fahrzeuglüftungssystems</strong> -
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Die Erfindung betrifft ein Fahrzeuglüftungssystem (1) zum Belüften einer Fahrgastzelle (2) eines Fahrzeugs (3), mit einem Umluftpfad (5). Die Erfindung ist gekennzeichnet durch eine wenigstens abschnittsweise in einen Umluftansaugbereich (4) des Umluftpads (5) hineinreichende Sterilisationseinrichtung (6), wobei die Sterilisationseinrichtung (6) dazu eingerichtet ist von einem aus der Fahrgastzelle (2) entnommenen Luftstrom getragene Schadstoffe zu inaktivieren und/oder abzutöten.</p></li>
</ul>
<img alt="embedded image" id="EMI-D00000"/>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE313868337">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The use of human serum albumin (HSA) and Cannabigerol (CBG) as active ingredients in a composition for use in the treatment of Coronavirus (Covid-19) and its symptoms</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU313251184">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The use of human serum albumin (HSA) and Cannabigerol (CBG) as active ingredients in a composition for use in the treatment of Coronavirus (Covid-19) and its symptoms</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU313251182">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>"AYURVEDIC PROPRIETARY MEDICINE FOR TREATMENT OF SEVERWE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2."</strong> - AbstractAyurvedic Proprietary Medicine for treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)In one of the aspect of the present invention it is provided that Polyherbal combinations called Coufex (syrup) is prepared as Ayurvedic Proprietary Medicine , Aqueous Extracts Mixing with Sugar Syrup form the following herbal aqueous extract coriandrum sativum was used for the formulation of protek.Further another Polyherbal combination protek as syrup is prepared by the combining an aqueous extract of the medicinal herbs including Emblica officinalis, Terminalia chebula, Terminalia belerica, Aegle marmelos, Zingiber officinale, Ocimum sanctum, Adatoda zeylanica, Piper lingum, Andrographis panivulata, Coriandrum sativum, Tinospora cordiofolia, cuminum cyminum,piper nigrum was used for the formulation of Coufex. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN312324209">link</a></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mund-Nasen-Bedeckung</strong> -
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Mund-Nasen-Bedeckung (1), wobei die Mund-Nasen-Bedeckung (1) mindestens an einem Ohr eines Trägers magnetisch befestigbar ist.</p></li>
</ul>
<img alt="embedded image" id="EMI-D00000"/>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE313866760">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Haptens, hapten conjugates, compositions thereof and method for their preparation and use</strong> - A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU311608060">link</a></p></li>
</ul>
<script>AOS.init();</script></body></html>

454
archive-daily-dose/22 January, 2021.html Normal file
View File

@ -0,0 +1,454 @@
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><head>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<meta content="text/css" http-equiv="Content-Style-Type"/>
<meta content="pandoc" name="generator"/>
<title></title>
<style type="text/css">code{white-space: pre;}</style>
<title>Daily-Dose</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><style>*{overflow-x:hidden;}</style><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="daily-dose">Daily-Dose</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-new-yorker">From New Yorker</a></li>
<li><a href="#from-vox">From Vox</a></li>
<li><a href="#from-the-hindu-sports">From The Hindu: Sports</a></li>
<li><a href="#from-the-hindu-national-news">From The Hindu: National News</a></li>
<li><a href="#from-bbc-europe">From BBC: Europe</a></li>
<li><a href="#from-ars-technica">From Ars Technica</a></li>
<li><a href="#from-jokes-subreddit">From Jokes Subreddit</a></li>
</ul>
<h1 data-aos="fade-right" id="from-new-yorker">From New Yorker</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Janet Yellen’s Confirmation Hearing Provides a Glimpse Into the Biden Era</strong> - Three topics are set to dominate the Administration’s economic agenda: the pandemic, spending and taxes, and China. - <a href="https://www.newyorker.com/news/our-columnists/janet-yellens-confirmation-hearing-provides-a-glimpse-into-the-biden-era">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Alexey Navalny’s Fearless Return to Russia</strong> - The Russian dissident’s superpower is his ability to show people what they have always known about the Putin regime but had the option of pretending away. - <a href="https://www.newyorker.com/news/our-columnists/alexey-navalnys-fearless-return-to-russia">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Obituary for a Failed Presidency</strong> - In the end, Donald Trump was everything his haters feared—a chaos candidate who became a chaos President. - <a href="https://www.newyorker.com/news/letter-from-trumps-washington/obituary-for-a-failed-presidency">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Week the Trump Supporters Disappeared</strong> - In Washington, D.C., our leaders sealed themselves off from a rebel force that didn’t arrive. - <a href="https://www.newyorker.com/news/the-political-scene/the-week-the-trump-supporters-disappeared">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Can Joe Biden Save American Catholicism from the Far Right?</strong> - Biden is the kind of flexible, independent-minded Catholic whom many bishops have spent their careers taking to task—and many progressive Catholics see as akin to themselves. - <a href="https://www.newyorker.com/news/daily-comment/can-joe-biden-save-american-catholicism-from-the-far-right">link</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-vox">From Vox</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Most Americans are open to Biden using executive action</strong> -
<figure>
<img alt="Biden waves while wearing a mask." src="https://cdn.vox-cdn.com/thumbor/9DTxnUs16A_zwi7N_6Xk0yCoAAo=/0x0:4864x3648/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/68704579/1297618985.0.jpg"/>
<figcaption>
US President Joe Biden walks the abbreviated parade route after his inauguration on January 20, 2021, in Washington, DC.  | Patrick Smith/Getty Images
</figcaption>
</figure></li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
There’s strong support for executive actions that preserve DACA and roll back Trump’s environmental regulations.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="YcYcAj">
A majority of Americans are open to President Joe Biden using executive action to advance policy priorities more quickly — but support varies significantly depending on the issue area.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="KX8qLB">
<a href="https://filesforprogress.org/datasets/2021/1/dfp_vox_biden_eo_polling.pdf">According to a new poll from Vox and Data for Progress</a>, only 18 percent of likely voters think Biden should use executive action whenever he can to implement his policy agenda, while 41 percent would back him using it on a case-by-case basis and 32 percent do not think he should take this route at all. Support also fluctuates by party: Just 10 percent of Democrats don’t think Biden should use executive action at all, while 57 percent of Republicans feel this way.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="cXzE2d">
As the Biden administration has already made clear, there’s a lot that he can do to both reverse Trump-era regulations and advance new ones without congressional approval. <a href="https://www.vox.com/22240617/biden-executive-actions-orders-covid-19-immigration-racial-justice">Per Vox’s German Lopez</a>, Biden signed 17 executive actions on his first day, addressing a wide range of subjects including a mask mandate on federal property, America’s involvement in the Paris climate agreement, and an extension of federal eviction moratoriums.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ikCKno">
The Vox/DFP poll, which was fielded on January 6 and 7, revealed strong support for Biden to use executive action on various fronts, including to enroll more people in the Deferred Action for Childhood Arrivals program, which protects undocumented immigrants who came to the US as children from deportation. Sixty percent of people, including 81 percent of Democrats, 64 percent of independents, and 36 percent of Republicans, support this action. Biden on Wednesday signed a proposal that helps preserve DACA and calls on Congress to approve legislation that would provide a path to citizenship for recipients.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="zYfgwu">
Biden’s use of executive actions is both a way to expedite rollbacks of Trump’s executive initiatives and a necessity to advance some efforts — like a swift vaccine rollout — given the current political reality. As emerging Republican pushback to Biden’s stimulus plan indicates, getting enough GOP support to reach 60 votes in the Senate is poised to be a challenge, and it could take much longer to advance bills with bipartisan backing. Given this dynamic, executive action enables Biden to move far more quickly to address the urgent nature of the ongoing crisis.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="v1rtfu">
The poll surveyed 1,156 likely voters and had a 2.9 percentage point margin of error.
</p>
<h3 id="bY6Hhb">
There’s strong support for Biden to use executive action on some areas
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="zMHyEy">
Support for Biden’s use of executive action depends on the issue area. This poll, ultimately, wound up covering policies the president has already addressed, as well as several that he hasn’t yet.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="j3m6G6">
Among the subjects that get widespread support in addition to increasing access to DACA: 70 percent of people think he should go it alone in order to increase access to food and housing aid, and 66 percent support his ability to encourage government agencies to use products that are sustainable and made using fair labor practices.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ahg4zh">
Restoring regulations that protect the environment (51 percent), withdrawing US combat troops from Afghanistan (54 percent), and expanding banking services offered by the US Postal Service (51 percent) all garnered a narrow majority of support as well.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="pCkaxq">
A few other areas, including abolishing the federal death penalty (35 percent) and undoing Trump’s travel ban (39 percent), were more contentious. Both issues broke heavily along party lines: A majority of Democrats would back Biden taking actions on both fronts, while roughly 19 percent of Republicans would.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="W1nu14">
Biden has already rolled back the travel ban as well as revoked a permit for the Keystone XL pipeline, among his efforts. Additional executive actions could well be on the horizon, depending on what he’s able to tackle in this way — and the type of opposition policies face in Congress.
</p>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>What Biden can do to fix America’s Covid-19 vaccine mess</strong> -
<figure>
<img alt="President Joe Biden on the campaign trail, wearing a mask and making the “okay” sign with one hand.." src="https://cdn.vox-cdn.com/thumbor/CFVPVDlKR1zKwUFNWwmqwcUENVA=/0x0:4949x3712/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/68704503/1228643735.0.jpg"/>
<figcaption>
Then-presidential candidate Joe Biden on the campaign trail in September 2020. | Jim Watson/AFP via Getty Images
</figcaption>
</figure></li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The vaccine rollout hasn’t gone as smoothly as hoped. Here’s how to fix it.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="4SP7jG">
One of President Joe Biden’s most pressing tasks is speeding up America’s Covid-19 vaccination efforts.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="zHEME9">
Vaccines are the US’s way out of the <a href="https://www.vox.com/coronavirus-covid19/">pandemic</a>. But the vast majority of Americans — perhaps 70 percent or more, though <a href="https://www.who.int/news-room/q-a-detail/herd-immunity-lockdowns-and-covid-19">we don’t know for sure</a> — will have to be inoculated to reach herd immunity or protect at least most of the population. That means vaccinating hundreds of millions of people.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ryDdPV">
The US <a href="https://www.vox.com/future-perfect/22213208/covid-19-vaccine-rollout-coronavirus-distribution">isn’t on track</a> to do that quickly. Former President Donald Trump’s administration <a href="https://www.cnbc.com/video/2020/12/18/vice-president-mike-pence-speaks-after-receiving-the-covid-19-vaccine-i-didnt-feel-a-thing.html">aimed to vaccinate</a> 20 million Americans by the end of 2020. Three weeks into 2021, slightly more than <a href="https://covid.cdc.gov/covid-data-tracker/#vaccinations">15 million</a> have gotten at least one dose. The Trump administration <a href="https://twitter.com/mitchellreports/status/1344098443598442498">resisted</a> a more hands-on approach that could get the process moving faster, while <a href="https://ourworldindata.org/grapher/covid-vaccination-doses-per-capita?tab=chart&amp;stackMode=absolute&amp;time=latest&amp;region=World">other countries</a> that acted quickly have been able to surpass or catch up to the US.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="xt3hEG">
As part of his <a href="https://www.vox.com/future-perfect/22232082/joe-biden-economic-stimulus-plan-covid-19-coronavirus">$400 billion Covid-19 proposal</a> and <a href="https://www.vox.com/e/21997507">national vaccine plan</a>, Biden has promised 100 million shots in 100 days, enough to fully vaccinate 50 million people with the two-shot vaccine. But to achieve — and hopefully exceed, as some experts say is needed — that goal, he’ll have to solve problems with the vaccine distribution chain’s “last mile”: from storage and distribution facilities to actual patients. That requires more federal support and coordination to help state and local governments and health care facilities work through staffing, scheduling, equipment, and other concerns.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="fQV5hL">
In the coming months, as vaccine distribution expands to a wider population, new issues are certain to arise. While not all of these are foreseeable, experts say there are ways to at least plan for addressing them quickly: establishing backup plans, staying in close communication with vaccinators on the ground, constantly surveilling the supply chain’s many moving parts to clear bottlenecks as they come up, and creating a public education campaign to convince <a href="https://www.usatoday.com/story/news/2021/01/05/trust-covid-19-vaccine-increasing-after-months-decline/4134805001/">more skeptical Americans</a>.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="LO9Dfe">
All of this was bound to be difficult from the start. Experts have repeatedly noted that, given both its size and urgency, this will be the biggest vaccination campaign in US history. Some have compared the work it requires to that of the New Deal or World War II. There will be serious challenges and, inevitably, mistakes.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="5woGcX">
But tens of thousands of lives are at stake. <a href="https://coronavirus.jhu.edu/map.html">More than 400,000 people</a> have died in the US from Covid-19 — a death rate that, when controlled for population, is <a href="https://ourworldindata.org/coronavirus-data-explorer?zoomToSelection=true&amp;time=2019-12-31..latest&amp;country=CAN~USA&amp;region=World&amp;deathsMetric=true&amp;interval=total&amp;perCapita=true&amp;smoothing=0&amp;pickerMetric=location&amp;pickerSort=asc">more than 2.5 times</a> that of neighboring Canada. With <a href="https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html">more than 3,000 people</a> on average dying of Covid-19 each day, every day that passes without mass vaccinations means another day on which thousands of lives are likely lost.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="FUYYcb">
Saving those lives begins with Biden embracing his new powers of the presidency.
</p>
<div class="c-float-right">
<div id="WxqAwl">
<div>
</div>
</div>
</div>
<h3 id="iC2sQp">
Biden must fill the void of federal leadership
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="BrVrnH">
Trump never offered much leadership on the pandemic, with his administration <a href="https://www.vox.com/future-perfect/21366624/trump-covid-coronavirus-pandemic-failure">seemingly opposed</a> to a much larger federal role from the beginning. When asked about a more hands-on federal approach to vaccines, Brett Giroir, Trump’s assistant secretary at HHS, compared the idea to a federal invasion: “The federal government doesn’t invade Texas or Montana and provide shots to people.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Go4bgW">
No one is talking about the Army taking over the Texas Capitol to forcibly administer vaccines. What’s needed, experts say, is for the federal government to provide more communication, guidance, coordination, and support, especially when states ask for it.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="fagQN1">
That begins with the “last mile” of the vaccine supply chain. It’s at this point, as vaccines go from a storage facility to patients, that things appear to have fallen apart in the US. Freezers <a href="https://www.latimes.com/california/story/2021-01-04/freezer-broken-california-town-had-to-use-or-lose-vaccine-shots">broke down</a> in California. People in West Virginia <a href="https://www.nytimes.com/2020/12/31/us/west-virginia-covid-vaccine-regeneron.html">mistakenly got</a> an experimental Covid-19 treatment instead of a vaccine. Seniors in Florida <a href="https://www.npr.org/2021/01/02/952897252/seniors-in-florida-camp-overnight-to-get-vaccine">waited in long lines</a> to get their shot. Health care workers in New York <a href="https://www.nytimes.com/2020/12/24/nyregion/nyc-hospital-workers-covid-19-vaccine.html">tried to cheat the system</a> to jump ahead in line.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="9Kcrmw">
Across the country, facilities <a href="https://prospect.org/coronavirus/unsanitized-america-vaccine-rollout-should-infuriate-you/">have complained</a> they don’t have the staff to administer the doses they have, as health care workers deal with a surge of Covid-19 patients and workers of all kinds fall sick themselves. Others <a href="https://www.statnews.com/2020/12/29/public-health-experts-grow-frustrated-with-pace-of-covid-19-vaccine-rollout/">have said</a> it’s impossible to plan ahead because they often don’t know how many doses or what type of vaccine they’re getting from the feds until the day the shipment arrives.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="V5YRiS">
The Trump administration suggested it wasn’t responsible for fixing these problems: It sent the vaccine doses to states, and it was on the states to distribute those doses from there.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="BWrHS8">
But there are some things the federal government could do, said Nada Sanders, a distinguished professor of supply chain management at Northeastern University. One is called “backward scheduling”: The Biden administration could partner with states to set a goal for how many people to vaccinate and then work backward, going from injecting the vaccine to the factory where the dose was produced in order to figure out what’s needed at every step. This won’t anticipate every single problem, but it will at least give officials a way to prepare.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="mYLw6f">
Bottlenecks “can and will occur,” Sanders told me. “It is just part of managing a supply chain. That is why it must be monitored in real time and bottlenecks addressed as they are forming, well before they become acute.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="L7SsWQ">
As distribution expands, more of these supply bottlenecks will pop up. Already, there have been reports of shortages of <a href="https://abc7chicago.com/covid-vaccine-dry-ice-storage-stock-pfizer/8748465/">dry ice</a>, <a href="https://www.npr.org/2021/01/03/953045468/covid-19-cases-surge-in-u-s-as-vaccinations-fall-below-government-predictions">small glass vials</a>, and <a href="https://www.nytimes.com/2020/12/22/us/politics/pfizer-vaccine-doses.html">materials for vaccine doses</a>. The Trump administration missed its <a href="https://www.hhs.gov/about/leadership/secretary/speeches/2020-speeches/remarks-at-vaccine-roundtable-with-vice-president-pence.html">own goal</a> of 40 million doses to states by the end of 2020, and was still millions short <a href="https://covid.cdc.gov/covid-data-tracker/#vaccinations">three weeks into January</a>.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="MNBHnz">
As we saw with Covid-19 testing, fixing these initial problems won’t solve everything for good. When one part of the supply chain is fixed, growing capacity enables more demand along other parts of the chain, leading to new bottlenecks popping up.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="vdQDM9">
The idea is to be ready for these problems and to use federal tools — such as the Defense Production Act, which can be used to boost production of needed materials — to smooth out issues as they arise. It also means working with flexibility and adaptability, given that unexpected problems can come up at any time.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="i5IT4e">
In some cases, the feds will need to provide direct resources to local and state governments. This is another area in which the Trump administration fell short: State groups spent months lobbying for $8 billion to build out vaccine infrastructure, but the administration <a href="https://www.statnews.com/2020/12/29/public-health-experts-grow-frustrated-with-pace-of-covid-19-vaccine-rollout/">gave them only $340 million</a>. It wasn’t until late December, when Congress and Trump passed a second stimulus package, that the federal government finally allocated the billions states had asked for.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="kD9IwT">
Even that came too late. States really needed the money to plan for vaccination efforts before they were underway, and some state officials say they need even more now that they’re actually dealing with a messy rollout.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="nE75b0">
The Biden administration will also eventually have to convince people to get vaccinated, including some of the <a href="https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/">roughly quarter of Americans</a> who are hesitant. That will require a large public education and awareness campaign, and probably some creativity and help from others — for instance, maybe having Taylor Swift or LeBron James get vaccinated on camera. Trump doing the same could help persuade his supporters, many of whom tend to be more skeptical about needing a vaccine. The US won’t be able to convince everyone to get a shot, but 100 percent compliance isn’t needed for herd immunity and sufficient protection.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="P1aHjA">
Biden has already promised much of this in his <a href="https://chorus.voxmedia.com/compose/e152fd6f-446c-45b3-989a-7e9137bd2dde">Covid-19 proposal</a> and <a href="https://www.vox.com/e/21997507">vaccine plan</a>, which include more support to states and proposals for mass vaccination centers and mobile units. The question now is how and whether these things are actually implemented.
</p>
<h3 id="QHgY5D">
This isn’t going to be easy, but it’s possible
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="1ids6u">
The current mishaps with the vaccine rollout are particularly concerning because this was <a href="https://www.theatlantic.com/health/archive/2021/01/next-phase-vaccination-will-be-even-harder/617595/">supposed to be the easier part</a>. The first groups getting vaccinated were relatively easy to target — officials should know where health care workers and nursing home residents are and have medical staff nearby. With vaccine allowances now expanding to more individuals in further-flung places, vaccination campaigns stand to get much harder.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Xp77FP">
“I thought the first month would go smoothly, and then we’d hit the big crash as the decisions became more complex,” Julie Swann, a vaccine distribution expert at North Carolina State University, told me.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="wwAeGD">
Experts have warned all along that the later parts of the US’s Covid-19 vaccine campaign would be an especially massive, complicated undertaking. We don’t yet know all of the problems that will arise in the coming months as more and more vaccines are distributed. “Ultimately, it is difficult to give [vaccines] out and prioritize it for a population,” Swann said.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="bjqgoi">
But <a href="https://ourworldindata.org/grapher/covid-vaccination-doses-per-capita?tab=chart&amp;stackMode=absolute&amp;time=latest&amp;region=World">other countries</a> have shown it can be done better. Israel is vaccinating people at seven times the rate of the US, and the United Arab Emirates, Bahrain, and United Kingdom are also ahead of the US. Countries that got a later start than America on vaccines, like Denmark and Ireland, are rapidly catching up.
</p>
<figure class="e-image">
<pre><code> &lt;img alt="A chart of vaccination rates in different countries." src="https://cdn.vox-cdn.com/thumbor/Qc1AJis-jyDyy8pvftft2pCX2Qw=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/22250872/covid_vaccination_doses_per_capita.png" /&gt;
&lt;cite&gt;&lt;a class="ql-link" href="https://ourworldindata.org/grapher/covid-vaccination-doses-per-capita?tab=chart&amp;amp;stackMode=absolute&amp;amp;time=latest&amp;amp;region=World" target="_blank"&gt;Our World in Data&lt;/a&gt;&lt;/cite&gt;</code></pre>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="w7Dfm0">
Mathematically, the current campaign simply isn’t quick enough. At the current rate of <a href="https://ourworldindata.org/covid-vaccinations">900,000 vaccinations per day</a>, it would take more than 250 days — into the fall — to reach what experts believe could be herd immunity for Covid-19. Many experts have called for finishing the vaccine campaign this summer, before the next school year, a possible fall surge, and another dangerous mutation of the virus. A months-longer undertaking could result in tens of thousands more deaths.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="5Jr2y5">
There’s no reason the US, as the wealthiest country in the world, should uniquely struggle so much with this. The country has done big vaccination campaigns before — every year with flu shots, in fact — and it’s how America eradicated diseases such as smallpox, polio, and measles within its borders. It’s not easy, but it’s absolutely possible.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="vAariT">
The key, though, is to leverage the powers of the federal government. Throughout the pandemic, America’s biggest failures have occurred when the federal government was slow to act or didn’t act at all. That was true with personal protective equipment for health care workers, as the Trump administration refused to make greater use of tools like the Defense Production Act. It was true for testing, as the administration <a href="https://www.vox.com/2020/4/28/21239729/coronavirus-testing-trump-plan-white-house">described itself</a> as a “supplier of last resort” and left state, local, and private actors to handle the bulk of the work. And it’s now true for vaccines, as Trump’s White House refused to get more involved.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="TWr69v">
This is a national crisis. Every state has far too many Covid-19 cases, based on <a href="https://www.vox.com/future-perfect/2020/7/31/21340268/coronavirus-pandemic-covid-state-maps-charts-data">Vox’s tracker of state epidemics</a>. Every state is failing to vaccinate its people quickly enough — <a href="https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/">few have administered more than 70 percent of their dose supply</a>. We need national solutions for this.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="6QCNmk">
As Ashish Jha, dean of the Brown University School of Public Health, <a href="https://www.washingtonpost.com/outlook/2020/12/31/vaccination-slow-trump-administration-states/">wrote in the Washington Post</a>, “For all this pandemic has taught us and cost us, it has demonstrated again that we are the United States and, especially in crisis, an effective federal government is essential.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="xGlHwG">
This is Biden’s promise, both on the campaign trail and in <a href="https://www.vox.com/future-perfect/22232082/joe-biden-economic-stimulus-plan-covid-19-coronavirus">his Covid-19 plan</a>: He’ll push a bigger role for the federal government. He now has a chance to show the idea can work. Lives depend on it.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="7dJU8M">
<a href="https://www.vox.com/weeds-newsletter"><em>Sign up for the Weeds newsletter</em></a><em>. Every Friday, you’ll get an explainer of a big policy story from the week, a look at important research that recently came out, and answers to reader questions — to guide you through the first 100 days of President Joe Biden’s administration.</em>
</p>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Why scientists are more worried about the Covid-19 variant discovered in South Africa</strong> -
<figure>
<img alt="A health care worker holding up a hypodermic needle connected to a vaccine vial." src="https://cdn.vox-cdn.com/thumbor/I8joa1n9NYkGABY3KESdW38-Fs4=/276x0:4000x2793/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/68700434/1230710698.0.jpg"/>
<figcaption>
The major concern is that Covid-19 mutations could undercut the effectiveness of the vaccines. | Emmanuel Dunand/AFP via Getty Images
</figcaption>
</figure></li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The variant carries mutations that may weaken the effect of vaccines.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="d0sPoh">
On January 15, <a href="https://www.washingtonpost.com/health/coronavirus-variant-dominant-us/2021/01/15/4420d814-5738-11eb-a817-e5e7f8a406d6_story.html">US public health officials</a> warned that a more contagious variant of the coronavirus that causes Covid-19 could dominate infections in the United States by March. That grim warning referred to B.1.1.7, a variant that was first identified in the United Kingdom.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ZsQeEH">
But now, one week later, scientists are increasingly concerned about another variant that emerged in South Africa.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="CCi9ml">
There’s evidence from several small, and not-yet-peer-reviewed, studies that mutations in the South Africa variant — known as 501Y.V2 and already present in <a href="https://www.who.int/publications/m/item/weekly-epidemiological-update---19-january-2021">at least 23 countries</a> — may have a higher risk of Covid-19 reinfection in people who’ve already been sick and still should have some immunity to the disease.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="xf817A">
Scientists haven’t confirmed that this variant is more contagious, though evidence is pointing in this direction. They’re also concerned that 501Y.V2 could have implications for <a href="https://www.vox.com/22219434/covid-19-drugs-treatment-monoclonal-antibodies-plasma-antiviral-regeneron-remdesivir">treatments for Covid-19</a>. Regeneron, a company that has developed a cocktail of two monoclonal antibodies as a therapy for patients with the illness, reported that 501Y.V2 may be able to evade one of the antibodies in its mix. The drug is still effective, but subsequent mutations could render it less so.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Dp9z08">
But perhaps most alarming is the prospect that the mutations in the variant could limit the effectiveness of existing vaccines, one of the best tools we have for controlling the pandemic.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="FfGElw">
The results of these recent studies are “a serious indication we have to look hard at how well vaccines might work,” Penny Moore, a virologist at the National Institute for Communicable Diseases in South Africa, told Vox. Taken together, they highlight the dangers of letting Covid-19 spread unchecked and also portend the challenges that lie ahead as the virus continues to evolve.
</p>
<h3 id="e57ni6">
What the 501Y.V2 coronavirus variant might mean for Covid-19 vaccines
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="kLbNu9">
Moore is the lead author of a <a href="https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1">new study</a> on 501Y.V2, out Tuesday as a preprint on BioRxiv. She and her team in South Africa took blood plasma samples from 44 people who had been infected with the coronavirus during the country’s first wave of infections last summer and then checked how their existing antibodies responded to 501Y.V2 as well as older variants.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="2aooEV">
The researchers sorted the plasma samples into categories — high and low antibody concentrations. Though antibodies can wane after infection, that doesn’t necessarily mean that protection fades completely. Another recent study showed that immunity stemming from infection <a href="https://www.vox.com/22230667/covid-immunity-natural-infection-symptoms-asymptomatic">lasts at least five months</a> in most people, so the antibodies in those who’ve had the virus should still shield against earlier versions of the virus if someone is infected again.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="gZEi8T">
In 21 cases — nearly half — the existing antibodies were powerless against the new variant when exposed in test tubes. This was especially true for plasma from people who had a mild previous infection, and lower levels of antibodies, to begin with.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="gDmO26">
The findings suggest immunity from previous versions of the virus might not help individuals fend off the new variant if they’re exposed, particularly if their prior case was mild or symptom-free.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="zpN5an">
For Fred Hutch Cancer Research Center scientist Trevor Bedford, who was not involved in the research, the study also came as a possible warning sign about the vaccines. As early as autumn this year, manufacturers may need to begin reformulating their shots to respond to the changes in the virus’s genetic code, he wrote on Twitter:
</p>
<div id="JDu11a">
<blockquote class="twitter-tweet">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" dir="ltr" lang="en">
501Y.V2 is still largely restricted to South Africa, but it (or other antigenically drifted variants) may spread more widely in the coming months. I would be planning this potential "strain" update for fall 2021. 9/10
</p>
— Trevor Bedford (<span class="citation">@trvrb</span>) <a href="https://twitter.com/trvrb/status/1351785371323940867?ref_src=twsrc%5Etfw">January 20, 2021</a>
</blockquote>
</div>
<h3 id="zefxap">
The specific mutation scientists are most worried about
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="byj2yv">
The 501Y.V2 variant carries one mutation of particular concern, known as E484K. This change appears in the part of the virus, the spike protein, that fits into the receptor in human cells. The spike protein is also the major target for the currently available mRNA vaccines, from Pfizer/BioNTech and Moderna.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="b4Koop">
“This mutation sits right in the middle of a hotspot in the spike,” Moore said. And it’s become notorious among virologists for its ability to elude coronavirus antibodies.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="4TtUl0">
Scientists have demonstrated how this might happen in other cell culture experiments. A new <a href="https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf">study</a>, also in preprint form from South African researchers, look a similar approach to Moore’s — testing how antibodies from six convalescent plasma donors react to 501Y.V2. But this time they used live virus, considered “the gold standard for these experiments,” said study co-author Richard Lessells, a University of KwaZulu-Natal infectious disease specialist. And their findings pointed in the same direction: 501Y.V2 can — at least in the lab — escape the antibody response elicited from a prior infection, and the E484K mutation “has the clearest association with immune escape.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="G8oot0">
In another recently published <a href="https://www.biorxiv.org/content/10.1101/2020.12.31.425021v1.full.pdf+html">BioRxiv preprint</a>, researchers in Washington state tracked how mutations altered the effectiveness of the antibody response in convalescent plasma of 11 people — and also found E484K had particularly potent antibody evasion capabilities.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Lo1xJZ">
Other variants of concern also carry the E484K mutation, including one first identified in Manaus, Brazil, known as P.1. And one case study suggests reinfection in some people might be possible when they’re exposed to the new variant.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="kr7bTf">
In a <a href="https://www.preprints.org/manuscript/202101.0132/v1">preprint</a>, researchers in Brazil documented the case of a 45-year-old Covid-19 patient with no co-morbidities, who months after her first bout with the illness, was reinfected with the new variant. The patient experienced more severe illness the second time around. While it’s limited evidence, it “might have major implications for public health policies, surveillance and immunization strategies,” the authors wrote.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="o9WDhq">
The study’s <a href="https://www.npr.org/sections/goatsandsoda/2021/01/21/958953434/reinfections-more-likely-with-new-coronavirus-variants-evidence-suggests">broader context</a> is also concerning: After more than three-quarters of the population in Manaus were estimated to be infected with the virus during a spring surge, cases are piling up again and hospitals are filling up. Researchers suspect reinfections with the new variant could be the driver.
</p>
<h3 id="T35h6m">
“The news is not all grim”
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="hyRblB">
But “the news is not all grim,” said University of Utah evolutionary virologist Stephen Goldstein. A <a href="https://www.biorxiv.org/content/10.1101/2021.01.15.426911v1.full.pdf+html">preprint</a>, led by Rockefeller University scientists, suggested antibodies from the vaccine may be more potent than antibodies from a previous infection. Researchers tested blood samples from 14 people who had received the Moderna vaccine and six who were immunized with the Pfizer/BioNTech vaccine. The E484K mutation, and two others found in the South Africa variant, were associated with a “small but significant” drop in antibody activity, the researchers found.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Bqkxee">
Still, said Goldstein, the antibodies induced by the vaccine “are so high to start with that the serum was still extremely potent against the mutant.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="OdN0wy">
To fully understand the threat the mutations pose to vaccines, we’ll need clinical trials involving vaccinated people, Moore said. “These studies flag a problem,” she added, “but how that translates to real life, we can’t tell.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="gmail-Onzb3w">
There’s also huge variation in immune responses among people, Goldstein said. In the Washington paper, the researchers found “extensive person-to-person variation” in how the mutations affected an individual’s antibody response.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="yqrpAu">
“The bottom line there is some reason for concern about reduced efficacy but efficacy will not fall off a cliff,” Goldstein said. “The vaccines are incredibly potent. ... If [they go] from 95% [efficacy] to 85% or even a little lower, we are still in great shape.” That’s why researchers and public health officials are heavily advocating for everyone to be vaccinated as quickly as possible.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="OdAX5o">
Even so, Moore cautioned: “From an immune escape point of view, the variants first detected in Brazil and South Africa are more of a concern but this is just the beginning. It’s our first indication that this virus can and does change.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="FoBiEn">
It’s possible that as we learn more, even the E484K mutation won’t turn out to undermine the vaccines. But there may be other changes to the virus lurking out there or evolving that will escape even vaccine-induced antibodies. “So many people now are infected that this is an arm’s race — the virus is now given every opportunity to mutate,” Moore said, “so it can take those steps on the pathway to immune escape more easily.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="IoN4qV">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="bke79b">
</p>
<h1 data-aos="fade-right" id="from-the-hindu-sports">From The Hindu: Sports</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>IPL auction likely on February 18: BCCI official</strong> - The player retention deadline ended on January 20 and the trading window closes on February 4</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>No one learns algebra in Class I, Pant will improve gradually as wicketkeeper, says Wriddhiman Saha</strong> - Saha said that he does not believe that Pant’s heroic show in Australia would close the door for him in the Indian team.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>I can be called a bowling all-rounder, I can bat, says Shardul Thakur</strong> - Thakur snared seven wickets and was India’s top scorer in the first innings of the Brisbane Test. India won the series 2-1.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Thailand Open: Rankireddy-Ponappa enter mixed doubles semifinals</strong> - Sixth seed Indian PV Sindhu will take on Thailand's Ratchanok Intanon in the women's singles quarterfinals</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Amid cancellation talk, Tokyo Olympics 'focused on hosting'</strong> - IOC President Thomas Bach and local organisers are pushing back against reports that the postponed Tokyo Olympics will be cancelled. Now set to open</p></li>
</ul>
<h1 data-aos="fade-right" id="from-the-hindu-national-news">From The Hindu: National News</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Sonu Sood moves Supreme Court against order on illegal construction notice</strong> - As per the BMC, the Bollywood actor had carried out structural changes to his residential building and converted it into a hotel without taking requisite permissions.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>NCP questions Centre on report about China building village in Arunachal Pradesh</strong> - How come one did not notice China's reported construction of homes in Indian territory, asks NCP leader Mahesh Tapase</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Arnab chats: CWC demands JPC probe on violation of nationals security, Official Secrets Act</strong> - The Congress Working Committee, the highest decision making body of the grand old party, passed a resolution to this effect.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Six killed in mine accident in Meghalaya</strong> - Police has lodged a case against the employer and investigation is underway</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>KS Alagiri urges Centre to withdraw its stance that States lack legislative competence to reserve seats in medical admissions</strong> - The Tamil Nadu Congress Committee president expressed shock over such submissions made by the Union Ministry of Health and Family Welfare</p></li>
</ul>
<h1 data-aos="fade-right" id="from-bbc-europe">From BBC: Europe</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Russia detains Navalny aides as protests go viral</strong> - Police hold aides to Putin critic Alexei Navalny as social media buzzes with plans for protests.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Coronavirus vaccine delays halt Pfizer jabs in parts of Europe</strong> - Some areas in Italy and Germany have to suspend vaccinations while they await Pfizer-Biontech deliveries,</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Diary Sow: Talented Senegal student 'sorry' after disappearing in France</strong> - Diary Sow, who raised concern by failing to return to school in Paris, had been "on a little break".</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Steinmetz trial: Swiss verdict for tycoon in Guinea mine corruption trial</strong> - The trial of Israeli businessman Beny Steinmetz is seen as the biggest corruption case in mining.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Brexit: Retailers warn they could burn goods stuck in EU</strong> - UK retailers may abandon goods EU customers want to return because it is cheaper than bringing them home.</p></li>
</ul>
<h1 data-aos="fade-right" id="from-ars-technica">From Ars Technica</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Chrome and Edge want to help with that password problem of yours</strong> - The line between browsers and password managers is blurring. - <a href="https://arstechnica.com/?p=1736748">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Rocket Report: Starship going offshore, Blue Origin may launch humans in April</strong> - "We're smarter as a team having been through this process." - <a href="https://arstechnica.com/?p=1736718">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A look at all of Biden’s changes to energy and environmental regulations</strong> - There's a lot going on in addition to some of Biden's high-profile moves. - <a href="https://arstechnica.com/?p=1736724">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Resident Evil VIII gets May release date, massive preview, playable demo</strong> - A free no-combat demo goes live on PlayStation 5 today; will hit Xbox, PC later. - <a href="https://arstechnica.com/?p=1736667">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>“Complete incompetence:” Biden team slams Trump’s COVID work</strong> - Biden Administration starts off with a flurry of orders, actions, and comprehensive plan. - <a href="https://arstechnica.com/?p=1736269">link</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-jokes-subreddit">From Jokes Subreddit</h1>
<ul>
<li><strong>Many years ago during my married days, I accidentally overturned my golf cart.</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Elizabeth, a very attractive and keen golfer, who lived in a villa on the golf course, heard the noise and called out: "Are you okay? What's your name?"
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
"It's John, and I'm okay, thanks," I replied as I pulled myself out of the twisted cart.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
"John," she said, (firm loose breasts undulating beneath her white silky robe) "forget your troubles. Come to my villa, rest a while and I'll help you get the cart up later."
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
"That's mighty nice of you," I answered, "but I don't think my wife would like it."
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
"Oh, come on now," Elizabeth insisted.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
She was so very pretty, very very sexy and very persuasive ... I was weak. "Well okay," I finally agreed but thought to myself, "my wife won't like it."
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
After a couple of restorative Scotch and waters, I thanked Elizabeth. "I feel a lot better now, but I know my wife is going to be really upset. So I'd best go now."
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
"Don't be silly!" Elizabeth said with a smile, letting her robe fall open slightly. "She won't know anything. By the way, where is she?"
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
"Still under the cart, I guess."
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/Gr8_J0K3R20"> /u/Gr8_J0K3R20 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/l2i7we/many_years_ago_during_my_married_days_i/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/l2i7we/many_years_ago_during_my_married_days_i/">[comments]</a></span></p></li>
<li><strong>An Irish fellow in New York turns to the gentleman next to him....</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“Well hey there friend! Where do ya hail from?”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“I’m from Ireland.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“No kidding! I’m from Ireland myself! What part of Ireland?”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“Grew up in Wexford.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“Wexford?! No kidding! I grew up in Wexford myself!”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“Well what are the chances of that?! Say, what secondary school did you go to?”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“I went to St Peters Secondary”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“ St Peters Secondary?! I went to St Peters Secondary! I’ll be darned! What year did you graduate?”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“1979”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“1979??!! That’s the year I graduated! What are the chances of that?!!”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Well as these 2 guys are just flabbergasted at the chances of this meeting, another guy at the end of the bar is watching curiously. He calls over to the bartender &amp; asks “hey what on earth is going on over there?”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
To which the bartender replies, “ah nothing. Just the O’Malley twins drunk again.”
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/Prossdog"> /u/Prossdog </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/l242t4/an_irish_fellow_in_new_york_turns_to_the/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/l242t4/an_irish_fellow_in_new_york_turns_to_the/">[comments]</a></span></p></li>
<li><strong>If pronouncing my b's as v's makes me sound Russian,</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Then soviet.
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/Dankcompany69"> /u/Dankcompany69 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/l2hq12/if_pronouncing_my_bs_as_vs_makes_me_sound_russian/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/l2hq12/if_pronouncing_my_bs_as_vs_makes_me_sound_russian/">[comments]</a></span></p></li>
<li><strong>My favorite movie is The Hunchback of Notre Dame.</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
I love a protagonist with a twisted back story.
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/The_Flying_Hawaiian"> /u/The_Flying_Hawaiian </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/l2k7se/my_favorite_movie_is_the_hunchback_of_notre_dame/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/l2k7se/my_favorite_movie_is_the_hunchback_of_notre_dame/">[comments]</a></span></p></li>
<li><strong>Once I saw this guy on a bridge about to jump. I said, "Don't do it!" He said, "Nobody loves me." I said, "God loves you. Do you believe in God?"</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
He said, "Yes." I said, "Are you a Christian or a Jew?" He said, "A Christian." I said, "Me, too! Protestant or Catholic?" He said, "Protestant." I said, "Me, too! What franchise?" He said, "Baptist." I said, "Me, too! Northern Baptist or Southern Baptist?" He said, "Northern Baptist." I said, "Me, too! Northern Conservative Baptist or Northern Liberal Baptist?"
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
He said, "Northern Conservative Baptist." I said, "Me, too! Northern Conservative Baptist Great Lakes Region, or Northern Conservative Baptist Eastern Region?" He said, "Northern Conservative Baptist Great Lakes Region." I said, "Me, too!"
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Northern Conservative Baptist Great Lakes Region Council of 1879, or Northern Conservative Baptist Great Lakes Region Council of 1912?" He said, "Northern Conservative Baptist Great Lakes Region Council of 1912." I said, "Die, heretic!" And I pushed him over.
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/rlemmie"> /u/rlemmie </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/l25f3a/once_i_saw_this_guy_on_a_bridge_about_to_jump_i/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/l25f3a/once_i_saw_this_guy_on_a_bridge_about_to_jump_i/">[comments]</a></span></p></li>
</ul>
<script>AOS.init();</script></body></html>

4
index.html
View File

File diff suppressed because one or more lines are too long